Triveni Bio Raises $65 Million Series C Financing to Drive Next-Stage Company Growth | |
Triveni Bio Doses First Healthy Volunteers with TRIV-573 Targeting KLK5/7 and IL-13 in Phase 1 Trial | |
Ovation and PrecisionLife Identify First Potential Genetic Biomarkers to Predict GLP-1 Efficacy Response | |
Ankyra Therapeutics Presents First Preclinical Data on ANK-203 | |
Compass Therapeutics Announces Key Leadership Appointments | |
Triveni Bio Named to Fierce Biotech's 2025 Fierce 15 | |
